Difference Between CDK Inhibitors
What is the difference between the CDK inhibitors?
Diagnosis & Disease Information
Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.
Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
What Is The Optimal Sequencing of Novel Agents for CLL?
Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.
Combination Drug Therapy May Prevent Tumors From Sidestepping Kinase Inhibitors
New research has shed light on how some tumors continue their growth despite treatment with kinase inhibitors, and on how a combination of drugs can yield much better results.
Volasertib Demonstrates Antitumor Activity in Patients With Ovarian Cancer
A study compared the effectiveness of volasertib versus chemotherapy for treatment of platinum-resistant or -refractory ovarian cancer.
- Loading...
Loading...
Loading... 
Loading...